Elizabeth D. Ballard

Elizabeth D. Ballard

Auto-generated profile, based on publicly available information

Elizabeth D. Ballard

Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Archives of Pediatrics & Adolescent Medicine
Verified
Journal Article
Open access
PDF file
LHLisa M Horowitz
Lisa M Horowitz
JBJeffrey A. Bridge
Jeffrey A. Bridge
STStephen J. Teach
Stephen J. Teach
EBElizabeth Ballard
Elizabeth Ballard
JKJennifer Klima
Jennifer Klima
MPMaryland Pao
Maryland Pao
ObjectiveTo develop a brief screening instrument to assess the risk for suicide in pediatric emergency department patients.DesignA prospective, cross-sectional instrument-development study evaluated 17 candidate screening questions assessing suicide risk in young patients. The Suicidal Ideation Questionnaire served as the criterion standard.SettingThree urban, pediatric emergency departments associated with tertiary care teaching hospitals.ParticipantsA convenience sample of 524 patients aged 10 to 21 years who presented with either medical/surgical or psychiatric chief concerns to the emergency department between September 10, 2008, and January 5, 2011.Main ExposuresParticipants answered 17 candidate questions followed by the Suicidal Ideation Questionnaire.Main Outcome MeasuresSensitivity, specificity, predictive values, likelihood ratios, and area under the receiver operating characteristic curves of the best-fitting combinations of screening questions for detecting elevated risk for suicide.ResultsA total of 524 patients were screened (344 medical/surgical and 180 psychiatric). Fourteen of the medical/surgical patients (4%) and 84 of the psychiatric patients (47%) were at elevated suicide risk on the Suicidal Ideation Questionnaire. Of the 17 candidate questions, the best-fitting model comprised 4 questions assessing current thoughts of being better off dead, current wish to die, current suicidal ideation, and past suicide attempt. This model had a sensitivity of 96.9% (95% CI, 91.3-99.4), specificity of 87.6% (95% CI, 84.0-90.5), and negative predictive values of 99.7% (95% CI, 98.2-99.9) for medical/surgical patients and 96.9% (95% CI, 89.3-99.6) for psychiatric patients.ConclusionsA 4-question screening instrument, the Ask Suicide-Screening Questions (ASQ), with high sensitivity and negative predictive value, can identify the risk for suicide in patients presenting to pediatric emergency departments.

1 May 2017 in Biological Psychiatry
Verified
Journal Article
Closed access
MLMarc S. Lener
Marc S. Lener
MNMark J. Niciu
Mark J. Niciu
EBElizabeth D. Ballard
Elizabeth D. Ballard
MPMinkyung Park
Minkyung Park
LPLawrence T. Park
Lawrence T. Park
CZCarlos A. Zarate
Carlos A. Zarate

1 November 2014 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
EBElizabeth D. Ballard
Elizabeth D. Ballard
DIDawn F. Ionescu
Dawn F. Ionescu
JVJennifer L. Vande Voort
Jennifer L. Vande Voort
MNMark J. Niciu
Mark J. Niciu
ERErica M. Richards
Erica M. Richards
CZCarlos A. Zarate
Carlos A. Zarate

1 November 2012 in Pediatrics
Verified
Journal Article
Open access
PDF file
LWLori Wiener
Lori Wiener
SZSima Zadeh
Sima Zadeh
HBHaven Battles
Haven Battles
KBKristin Baird
Kristin Baird
EBElizabeth Ballard
Elizabeth Ballard
MPMaryland Pao
Maryland Pao
OBJECTIVE: The objective of this study was to assess and compare the usefulness, helpfulness, and stress associated with reviewing a previously adapted advance care planning guide, My Thoughts, My Wishes, My Voice, in comparison with the widely used adult document Five Wishes by adolescents and young adults (AYAs) living with a serious illness. METHODS: Fifty-two participants (age 16–28) living with metastatic or recurrent cancer or HIV infection (acquired at birth or early in life) were presented pages randomly from My Thoughts, My Wishes, My Voice and, Five Wishes, and asked to rank 25 items on several factors, including how likely they would be to complete each statement. Participant opinion on suggested changes in content, design, format, and style was obtained and resulted in development of a new document. RESULTS: AYAs living with a life-threatening illness want to be able to choose and record (1) the kind of medical treatment they want and do not want, (2) how they would liked to be cared for, (3) information for their family and friends to know, and (4) how they would like to be remembered. CONCLUSIONS: AYA views of what should be included in an advance care planning guide were incorporated into a new document, Voicing My Choices, that provides youth, families and providers an opportunity to reduce the silence around the dying process by allowing an opportunity to share one’s voice. We provide guidance on how to incorporate this tool into care.

22 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
EBElizabeth D. Ballard
Elizabeth D. Ballard
CZCarlos A. Zarate
Carlos A. Zarate
Ketamine produces immediate antidepressant effects and has inspired research into next-generation treatments. Ketamine also has short term dissociative effects, in which individuals report altered consciousness and perceptions of themselves and their environment. However, whether ketamine’s dissociative side effects are necessary for its antidepressant effects remains unclear. This perspective examines the relationship between dissociative effects and acute and longer-lasting antidepressant response to ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists. Presently, the literature does not support the conclusion that dissociation is necessary for antidepressant response to ketamine. However, further work is needed to explore the relationship between dissociation and antidepressant response at the molecular, biomarker, and psychological levels.

13 April 2015 in Therapeutic Advances in Chronic Disease
Verified
Journal Article
Open access
NINicolas D. Iadarola
Nicolas D. Iadarola
MNMark J. Niciu
Mark J. Niciu
ERErica M. Richards
Erica M. Richards
JVJennifer L. Vande Voort
Jennifer L. Vande Voort
EBElizabeth D. Ballard
Elizabeth D. Ballard
CZCarlos A. Zarate
Carlos A. Zarate
Current pharmacotherapies for major depressive disorder (MDD) and bipolar depression (BDep) have a distinct lag of onset that can generate great distress and impairment in patients. Furthermore, as demonstrated by several real-world effectiveness trials, their efficacy is limited. All approved antidepressant medications for MDD primarily act through monoaminergic mechanisms, agonists or antagonists with varying affinities for serotonin, norepinephrine and dopamine. The glutamate system has received much attention in recent years as an avenue for developing novel therapeutics. A single subanesthetic dose infusion of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has been shown to have rapid and potent antidepressant effects in treatment-resistant MDD and BDep. In a reverse translational framework, ketamine’s clinical efficacy has inspired many preclinical studies to explore glutamatergic mechanisms of antidepressant action. These studies have revealed enhanced synaptic plasticity/synaptogenesis via numerous molecular and cellular mechanisms: release of local translational inhibition of brain-derived neurotrophic factor and secretion from dendritic spines, mammalian target of rapamycin activation and glycogen synthase kinase-3 inhibition. Current efforts are focused on extending ketamine’s antidepressant efficacy, uncovering the neurobiological mechanisms responsible for ketamine’s antidepressant activity in biologically enriched subgroups, and identifying treatment response biomarkers to personalize antidepressant selection. Other NMDA receptor antagonists have been studied both preclinically and clinically, which have revealed relatively modest antidepressant effects compared with ketamine but potentially other favorable characteristics, for example, decreased dissociative or psychotomimetic effects; therefore, there is great interest in developing novel glutamatergic antidepressants with greater target specificity and/or decreased adverse effects.